SVR 12 | Relapse | p value | |
---|---|---|---|
total: 74 % (56) | total: 26 % (20) | ||
Age <65 years | 95 % (53) | 85 % (17) | 0.1698 |
Age ≥65 years | 5 % (3) | 15 % (3) | |
Female | 34 % (19) | 20 % (4) | 0.2445 |
Male | 66 % (37) | 80 % (16) | |
Non-cirrhotic | 64 % (36) | 35 % (7) | 0.0233 |
Cirrhotic | 36 % (20) | 65 % (13) | |
Treatment naive | 52 % (29) | 45 % (9) | 0.6024 |
Treatment experienced | 48 % (27) | 55 % (11) | |
HCV-RNA <6 (10E6 IU ml-1) at baseline | 79 % (44) | 85 % (17) | 0.5352 |
HCV-RNA ≥6 (10E6 IU ml-1) at baseline | 21 % (12) | 15 % (3) | |
HCV-RNA <12 (IU ml-1) after 4 weeks of treatment | 70 % (39) | 35 % (7) | 0.0065 |
HCV-RNA ≥12 (IU ml-1) after 4 weeks of treatment | 30 % (17) | 65 % (13) | |
Platelets <100 (10E3 μl-1) at baseline | 18 % (10) | 30 % (6) | 0.2529 |
Platelets ≥100 (10E3 μl-1) at baseline | 82 % (46) | 70 % (14) |